Effect of statin therapy on muscle symptoms: an individual participant data meta-analysis of large-scale, randomised, double-blind trials

Prevalence of statin intolerance: a meta-analysis

(2022) Ibadete Bytyçi et al.   EUROPEAN HEART JOURNAL

Step‐by‐step diagnosis and management of the nocebo/drucebo effect in statin‐associated muscle symptoms patients: a position paper from the International Lipid Expert Panel (ILEP)

(2022) Peter E. Penson et al.   Journal of Cachexia Sarcopenia and Muscle

Statin treatment and muscle symptoms: series of randomised, placebo controlled n-of-1 trials

(2021) Emily Herrett et al.   BMJ-British Medical Journal

Intensity of statin therapy and muscle symptoms: a network meta-analysis of 153 000 patients

(2021) John W Davis et al.   BMJ Open

Global Burden of Cardiovascular Diseases and Risk Factors, 1990–2019

(2020) Gregory A. Roth et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

N-of-1 Trial of a Statin, Placebo, or No Treatment to Assess Side Effects

(2020) Frances A. Wood et al.   NEW ENGLAND JOURNAL OF MEDICINE

Statin Safety and Associated Adverse Events: A Scientific Statement From the American Heart Association

(2019) Connie B. Newman et al.   ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY

Efficacy and safety of statin therapy in older people: a meta-analysis of individual participant data from 28 randomised controlled trials

(2019) Jane Armitage et al.   LANCET

Comparison of Conventional Lipoprotein Tests and Apolipoproteins in the Prediction of Cardiovascular Disease: Data from UK Biobank

(2019) Claire Welsh et al.   CIRCULATION

2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol

(2018) Scott M. Grundy et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

Adverse events associated with unblinded, but not with blinded, statin therapy in the Anglo-Scandinavian Cardiac Outcomes Trial—Lipid-Lowering Arm (ASCOT-LLA): a randomised double-blind placebo-controlled trial and its non-randomised non-blind extension phase

(2017) Ajay Gupta et al.   LANCET

Protocol for analyses of adverse event data from randomized controlled trials of statin therapy

(2016) C. Reith et al.   AMERICAN HEART JOURNAL

Efficacy and Tolerability of Evolocumab vs Ezetimibe in Patients With Muscle-Related Statin Intolerance

(2016) Steven E. Nissen et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

The nocebo effect in the context of statin intolerance

(2016) Jonathan A. Tobert et al.   Journal of Clinical Lipidology

Interpretation of the evidence for the efficacy and safety of statin therapy

(2016) Rory Collins et al.   LANCET

Efficacy and safety of alirocumab vs ezetimibe in statin-intolerant patients, with a statin rechallenge arm: The ODYSSEY ALTERNATIVE randomized trial

(2015) Patrick M. Moriarty et al.   Journal of Clinical Lipidology

Efficacy and safety of LDL-lowering therapy among men and women: meta-analysis of individual data from 174 000 participants in 27 randomised trials

(2015)   LANCET

A systematic review of statin-induced muscle problems in clinical trials

(2014) Harsha V. Ganga et al.   AMERICAN HEART JOURNAL

The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials

(2013)   LANCET

Should people at low risk of cardiovascular disease take a statin?

(2013) J. D. Abramson et al.   BMJ-British Medical Journal

Statin Use and Musculoskeletal Pain Among Adults With and Without Arthritis

(2012) Catherine Buettner et al.   AMERICAN JOURNAL OF MEDICINE

Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170 000 participants in 26 randomised trials

(2010)   LANCET

Intensive lowering of LDL cholesterol with 80 mg versus 20 mg simvastatin daily in 12 064 survivors of myocardial infarction: a double-blind randomised trial

(2010)   LANCET

Rosuvastatin and Cardiovascular Events in Patients Undergoing Hemodialysis

(2009) Bengt C. Fellström et al.   NEW ENGLAND JOURNAL OF MEDICINE

Effect of rosuvastatin in patients with chronic heart failure (the GISSI-HF trial): a randomised, double-blind, placebo-controlled trial

(2008) GISSI-HF investigators   LANCET

Rosuvastatin to Prevent Vascular Events in Men and Women with Elevated C-Reactive Protein

(2008) Paul M Ridker et al.   NEW ENGLAND JOURNAL OF MEDICINE